A review of smoking cessation: Potentially risky effects on prescribed medications

Journal of Clinical Nursing

Volumn 18, Issue 11, 2009, Pages 1533-1540

  Schaffer, Susan D ^a   Yoon, Saunjoo ^a   Zadezensky, Immo ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF NURSING   (United States)

^b Office of Biotechnology Products   (United States)

Author keywords

CYP1A2; Cytochrome P 450; Drug interaction; Nurses; Nursing; Smoking cessation

Indexed keywords

CYTOCHROME P450 1A2;

DRUG INTERACTION; HUMAN; MENTAL HEALTH; METABOLISM; PHARMACOKINETICS; REVIEW; SMOKING CESSATION;

CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; HUMANS; MENTAL HEALTH; PHARMACOKINETICS; SMOKING CESSATION;

EID: 65649121916     PISSN: 09621067     EISSN: 13652702     Source Type: Journal    
DOI: 10.1111/j.1365-2702.2008.02724.x     Document Type: Review

References (47)

1. ® (naratriptan) package insert (2003, May) GlaxoSmithKline. Research Triangle Park, NC.
2. Bachmann K, Shapiro R, Fulton R, Carroll FT Sullivan TJ (1979) Smoking and warfarin disposition. Clinical Pharmacology and Therapeutics 25, 309 315.
3. Bondolfi G, Morel F, Cretto S, Rachid F, Baumann P Rap CB (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Therapeutic Drug Monitoring 27, 539 543.
4. Brownlowe K Sola C (2008) Clozapine toxicity AR in smoking cessation and with ciprofloxacin. Psychosomatics 49, 176.
5. Bruno R, Vivier N, Montay G, Le Liboux A, Powe LK, Delumeau JC Rhodes GR (1997) Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clinical Pharmacology and Therapeutics 62, 518 526.
6. Burns M (1999) Management of narrow therapeutic index drugs. Journal of Thrombosis and Thrombolysis 7, 137 143.
7. Buxton ILO (2006) Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action and elimination. In Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton LL, Lazo J S Parker K L eds 11th ed, McGraw-Hill, New York, pp. 1 39.
8. Clinical Pharmacology (2008) Gold Standard Inc. Available at: http://www.goldstandard.com/ and http://cpip.gsm.com/ (accessed January 2008).
9. Colucci VJ Knapp JF (2001) Increase in international normalized ratio associated with smoking cessation. The Annals of Pharmacotherapy 35, 385 386.
10. Correia MA (2007) Drug biotransformation. In Basic and Clinical Pharmacology (Katzung BG ed Chap. 4, 10th ed. Lange Medical Books/McGraw Hill, New York. Available at: http://www.accessmedicine.com/content.aspx?aID=2504704 (accessed 1 December 2008).
11. Cusack BJ (2004) Pharmacokinetics in older persons. The American Journal of Geriatric Pharmacotherapy 2, 274 302.
12. Derenne JL Baldessarini RJ (2005) Clozapine toxicity AR associated with smoking cessation: case report. American Journal of Therapeutics 12, 469 471.
13. Dodick DW Martin V (2004) Triptans and CNS side effects: pharmacokinetics and metabolic mechanisms. Cephalalgia 24, 417 424.
14. Eliasson B, Attvall S, Taskinen MR Smith U (1997) Smoking cessation improves insulin sensitivity AR in healthy middle-aged men. European Journal of Clinical Investigation 27, 450 456.
15. Evans M Lewis GM (2005) Increase in international normalized ratio after smoking cessation in a patient receiving warfarin. Pharmacotherapy 25, 1656 1659.
16. ® (rivastigmine tartrate) package insert (2004, Oct) Novartis Pharmaceuticals Corp. East Hanover, NJ.
17. Faber MS Fuhr U (2004) Time response of cytochrome P450 1A2 activity AR on cessation of heavy smoking. Clinical Pharmacology and Therapeutics 76, 178 184.
18. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR Beers MH (2003) Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Archives of Internal Medicine 163, 2716 2724.
19. Fiore MC (Panel Chair 1996) Smoking Cessation: Clinical Practice Guideline No. 18. US Dept of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research AHCPR publication, 96-0692, Rockville, MD.
20. Fuhr U, Muller-Peltzer H, Kern R, Lopez-Rojas P, Junemann M, Harder S Staib AH (2002) Effects of grapefruit juice and smoking on verapamil concentrations in steady state. European Journal of Clinical Pharmacology 58, 45 53.
21. Grech-Belanger O, Gilbert M, Turgeon J LeBlanc PP (1985) Effect of cigarette smoking on mexiletine kinetics. Clinical Pharmacology and Therapeutics 37, 638 643.
22. Hansten PD Horn JR (2006) Cytochrome P450 enzymes and drug interactions, Table of Cytochrome P450 Substrates, Inhibitors, Inducers and P-glycoprotein (with footnotes). The Top 100 Drug Interactions - A Guide to Patient Management. H & H Publications, Edmonds, WA, pp. 160 174.
23. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA Davis CM (1986) Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Springer/Berlin) 90, 468 470.
24. Kroon LA (2007) Drug interactions with smoking. American Journal of Health-System Pharmacy 64, 1917 1921.
25. Lee BL, Benowitz NL Jacob P (1987) Cigarette abstinence, nicotine gum and theophylline disposition. Annals of Internal Medicine 106, 553 555.
26. de Leon J, Armstrong SC Cozza KL (2005) The dosing of atypical antipsychotics. Psychosomatics 46, 262 273.
27. MacLeod S, Sinha R, Kadlubar FF Lang NP (1997) Polymorphisms of CYP 1A1 and GSTM1 influence the in vivo function of CYP 1A2. Mutation Research 376, 135 142.
28. Madsbad S, McNair P Christensen MS (1980) Influence of smoking on insulin requirement and metabolic status in diabetes mellitus. Diabetes Care 3, 41 43.
29. Meyer JM (2001) Individual changes in clozapine levels after smoking cessation: results and a predictive model. Journal of Clinical Psychopharmacology 21, 569 574.
30. Oates JA (2006) The science of drug therapy. In Goodman & Gilman's, The Pharmacological Basis of Therapeutics, 11th edn Brunton LL, Lazo JS Parker KL eds). McGraw-Hill, New York, pp. 117 136.
31. ® (ramelteon) package insert (2006, Apr) Takeda Pharmaceutical Company Limited. Osaka, Japan.
32. Sanders-Bush E Mayer SE (2006) 5-Hydroxytryptamine (serotonin) receptor agonists and antagonists. In Goodman & Gilman's, The Pharmacological Basis of Therapeutics, 11th edn Brunton LL, Lazo JS Parker KL eds). McGraw-Hill, New York, pp. 308.
33. Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA Phillips B (2007) Clozapine case series. Psychosomatics 48, 170 175.
34. Schein JR (1995) Cigarette smoking and clinically significant drug interactions. The Annals of Pharmacotherapy 29, 1139 1148.
35. Sherman CB (1991) Health effects of cigarette smoking. Clinics in Chest Medicine 12, 643 658.
36. Skogh E, Bengtsson F Nordin C (1999) Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Therapeutic Drug Monitoring 21, 580.
37. Slama K (2008) Global perspective on tobacco control. Part 1: The global state of the tobacco epidemic. International Journal of Tuberculosis and Lung Disease 12, 3 7.
38. Spigset O, Carleborg L, Hedenmalm K Dahlqvist R (1995) Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clinical Pharmacology and Therapeutics 58, 399 403.
39. Tatro DS (2008) Drug Interaction Facts 2008: The Authority AR on Drug Interactions. Facts & Comparisons, Wolters Kluwer Health, St. Louis, Mo.
40. Turkoski BB (2002) Induction or inhibition: the complexity AR of cytochrome P450 enzymes and their imparct on drug interactions. Orthopaedic Nursing 21, 68 73.
41. Turnheim K (1998) Drug dosage in the elderly: is it rational? Drugs and Aging 13, 357 379.
42. Turnheim K (2004) Drug therapy in the elderly. Experimental Gerontology 39, 1731 1738.
43. United States Code of Federal Regulations 21CFR320.33(c). Available at: http://www.gpoaccess.gov/cfr/index.html (accessed 19 February, 2008).
44. U. S. Department of Health and Human Services (2000) Healthy People 2010, 2nd edn. U.S. Government Printing Office, Washington D.C.
45. World Health Organization (2003) Tools for Advancing Tobacco Control in the XXIst Century: Policy Recommendations for Smoking Cessation and Treatment of Tobacco Dependence e Silva VD ed World Health Organization, Switzerland.
46. Zevin S Benowitz NL (1999) Drug interactions with tobacco smoking: an update. Clinical Pharmacokinetics 36, 425 438.
47. Zullino DF, Delessert D, Eap CB, Preisig M Baumann P (2002) Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. International Clinical Psychopharamcology 17, 141 143.